Sanofi’s and Regeneron’s Duxipent Approved in China for Atopic Dermatitis

China has approved Sanofi’s and Regeneron’s Duxipent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not controlled with topical prescription therapies.  

China’s National Medical Products Administration identified Duxipent as urgently needed in clinical practice in China and gave it an expedited review. 

The monoclonal antibody is approved in more than 60 countries for the treatment of adults with moderate-to-severe atopic dermatitis.